EP4512471A3 - Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen - Google Patents

Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen Download PDF

Info

Publication number
EP4512471A3
EP4512471A3 EP24207715.4A EP24207715A EP4512471A3 EP 4512471 A3 EP4512471 A3 EP 4512471A3 EP 24207715 A EP24207715 A EP 24207715A EP 4512471 A3 EP4512471 A3 EP 4512471A3
Authority
EP
European Patent Office
Prior art keywords
dermatitis
areas
treatment
skin afflictions
afflictions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24207715.4A
Other languages
English (en)
French (fr)
Other versions
EP4512471A2 (de
Inventor
Frank Anthony SPALLITTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Attillaps Holdings
Original Assignee
Attillaps Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attillaps Holdings filed Critical Attillaps Holdings
Publication of EP4512471A2 publication Critical patent/EP4512471A2/de
Publication of EP4512471A3 publication Critical patent/EP4512471A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP24207715.4A 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen Pending EP4512471A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462014520P 2014-06-19 2014-06-19
EP22182867.6A EP4088724B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen
EP15809417.7A EP3157534B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen
PCT/US2015/036448 WO2015195928A1 (en) 2014-06-19 2015-06-18 Acetylcholinesterase inhibitors for treatment of dermatological conditions

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP22182867.6A Division EP4088724B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen
EP15809417.7A Division EP3157534B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen

Publications (2)

Publication Number Publication Date
EP4512471A2 EP4512471A2 (de) 2025-02-26
EP4512471A3 true EP4512471A3 (de) 2025-05-07

Family

ID=54936099

Family Applications (3)

Application Number Title Priority Date Filing Date
EP24207715.4A Pending EP4512471A3 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen
EP15809417.7A Active EP3157534B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen
EP22182867.6A Active EP4088724B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP15809417.7A Active EP3157534B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen
EP22182867.6A Active EP4088724B1 (de) 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen

Country Status (17)

Country Link
US (3) US10500183B2 (de)
EP (3) EP4512471A3 (de)
AU (1) AU2015277038B2 (de)
CA (1) CA2952838C (de)
CY (1) CY1126038T1 (de)
DK (1) DK3157534T3 (de)
ES (1) ES2925021T3 (de)
HR (1) HRP20220854T1 (de)
HU (1) HUE059303T2 (de)
LT (1) LT3157534T (de)
PL (1) PL3157534T3 (de)
PT (1) PT3157534T (de)
RS (1) RS63433B1 (de)
SI (1) SI3157534T1 (de)
SM (1) SMT202200283T1 (de)
WO (1) WO2015195928A1 (de)
ZA (1) ZA201700183B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126541A1 (en) * 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
US11446241B2 (en) * 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
WO2015017328A2 (en) * 2013-07-29 2015-02-05 Spallitta Frank Anthony Organophosphates for treating afflictions of the skin
LT3157534T (lt) 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
JP2019515052A (ja) * 2016-05-13 2019-06-06 デルノバ・インコーポレイテッドＤｅｌＮｏｖａ，Ｉｎｃ． 化学的除神経から生じる副作用の処置
CN109200051A (zh) * 2017-07-03 2019-01-15 南京和博生物医药有限公司 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
BE1025705B1 (fr) 2017-09-12 2019-06-18 Cosucra Groupe Warcoing Sa Amélioration de la maladie et des conditions générales de la volaille et du bétail à l'aide d'une racine chicorée séchée
WO2019118928A1 (en) 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019136221A1 (en) * 2018-01-05 2019-07-11 Attillaps Holdings Treating autoimmune disorders with chloroquine and/or hydroxychloroquine
WO2019136225A1 (en) * 2018-01-05 2019-07-11 Attillaps Holdings Treating dermatological conditions with chloroquine and/or hydroxychloroquine
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
WO2021102072A1 (en) * 2019-11-19 2021-05-27 Rythera Therapeutics, Inc. Composition and method for skin treatment
CN114829629A (zh) * 2019-12-19 2022-07-29 希尔氏宠物营养品公司 治疗和降低患上与犬科动物的升高的4-乙基苯基硫酸盐相关的病状的风险的组合物和方法以及鉴定有风险患上此类病状的犬科动物的方法
WO2021189077A1 (en) * 2020-03-18 2021-09-23 Chemistryrx Methods for treating acne
CN114099490A (zh) * 2021-12-30 2022-03-01 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 卡巴拉汀在制备促进缺血超长随意皮瓣存活的药物的作用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287733A1 (en) * 2004-10-12 2007-12-13 Ernir Snorrason Method of Treating Skin Diseases
US20130344128A1 (en) * 2005-04-30 2013-12-26 Tissuetech, Inc. Method for treating ocular demodex
WO2015017328A2 (en) * 2013-07-29 2015-02-05 Spallitta Frank Anthony Organophosphates for treating afflictions of the skin

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
DE4217396A1 (de) 1992-05-26 1993-12-02 Bayer Ag Metrifonat enthaltendes Arzneimittel
ES2244169T3 (es) 1998-02-09 2005-12-01 Bracco International B.V. Suministro direccionado de medios biologicamente activos.
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
EP1389911A1 (de) 2001-05-09 2004-02-25 Medicis Pharmaceutical Corporation Ectoparasitizide zusammensetzungen und verfahren zu ihrer verwendung
WO2003066009A1 (en) * 2002-02-08 2003-08-14 Merck & Co., Inc. Topical ivermectin composition
MXPA04013003A (es) 2002-06-19 2005-09-12 Fideline Composiciones de alomonas repelentes y kairomonas atractivas, para controlar aracnidos.
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US7899527B2 (en) * 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
US8012498B2 (en) * 2004-07-12 2011-09-06 Sandhya Goyal Topical gel formulation comprising organophosphate insecticide and preparation thereof
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
US8475818B2 (en) 2006-09-01 2013-07-02 E. I. De Pont De Nemours And Company Local topical administration formulations containing indoxacarb
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
BRPI0806666A8 (pt) 2007-01-16 2018-02-06 Tyratech Inc Composições e método para controle de praga
US20130052271A1 (en) * 2011-08-29 2013-02-28 Richard S. Sternasty Compositions and Methods for Treating Pain
FR2915489B1 (fr) * 2007-04-27 2009-07-31 Univ Henri Poincare Nancy I Et Phosphotriesterases hyperthermophiles mutees et leurs utilisations
EP2337544A2 (de) * 2007-04-30 2011-06-29 Living Proof, Inc. Verwendung von matrix-metalloproteinase-hemmern in der hautpflege
US7919522B2 (en) 2007-05-03 2011-04-05 Merial Limited Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds
CA2687679A1 (en) 2007-05-18 2008-11-27 Vivus, Inc. Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
GB0713790D0 (en) 2007-07-16 2007-08-22 Nettforsk As Method
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US8128968B2 (en) * 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
TW200924647A (en) 2007-08-30 2009-06-16 Schering Plough Ltd Local topical administration formulations containing fipronil
DE102007043006B4 (de) 2007-09-06 2010-04-08 Freie Universität Berlin Vorrichtung und Verfahren zur Exponierung eines Insekts mit einem Wirkstoff sowie Verfahren zur Bestimmung der Wirkung eines Wirkstoffs auf ein Insekt
EP2072501A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Aminobenzamidderivate als nützliche Wirkstoffe zur Parasitenkontrolle bei Tieren
WO2009127057A1 (en) 2008-04-15 2009-10-22 Innovactiv Inc. Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
BR112013001634A2 (pt) * 2010-07-23 2016-05-24 Takeda Pharmaceutical composto ou sal, medicamento, métodos para a profilaxia ou tratamento da arteriosclerose, da diabete ou obesidade em um mamífero, e, uso do composto ou sal
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
JP2014028758A (ja) 2010-11-19 2014-02-13 Nissan Chem Ind Ltd 寄生虫及び衛生害虫防除剤
BR112013025288A2 (pt) 2011-03-31 2016-10-18 Bayer Cropscience Lp misturas pesticidas
FR2975004B1 (fr) * 2011-05-13 2013-06-28 Expanscience Lab Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
CA2940871C (en) * 2013-03-13 2020-10-20 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
US11446241B2 (en) * 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
LT3157534T (lt) 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287733A1 (en) * 2004-10-12 2007-12-13 Ernir Snorrason Method of Treating Skin Diseases
US20130344128A1 (en) * 2005-04-30 2013-12-26 Tissuetech, Inc. Method for treating ocular demodex
WO2015017328A2 (en) * 2013-07-29 2015-02-05 Spallitta Frank Anthony Organophosphates for treating afflictions of the skin

Also Published As

Publication number Publication date
US20170135978A1 (en) 2017-05-18
WO2015195928A1 (en) 2015-12-23
LT3157534T (lt) 2022-09-12
ES2925021T3 (es) 2022-10-13
US20220096420A1 (en) 2022-03-31
DK3157534T3 (da) 2022-08-22
RS63433B1 (sr) 2022-08-31
CA2952838C (en) 2023-09-05
HUE059303T2 (hu) 2022-11-28
EP4088724C0 (de) 2024-10-23
US10500183B2 (en) 2019-12-10
PL3157534T3 (pl) 2022-09-12
US20200281885A1 (en) 2020-09-10
ZA201700183B (en) 2020-05-27
HRP20220854T1 (hr) 2022-10-14
AU2015277038A1 (en) 2017-02-02
CY1126038T1 (el) 2023-11-15
EP4512471A2 (de) 2025-02-26
PT3157534T (pt) 2022-08-04
US11045442B2 (en) 2021-06-29
EP3157534B1 (de) 2022-07-06
EP3157534A4 (de) 2018-03-14
CA2952838A1 (en) 2015-12-23
EP4088724B1 (de) 2024-10-23
AU2015277038B2 (en) 2020-09-17
SI3157534T1 (sl) 2022-08-31
EP4088724A1 (de) 2022-11-16
SMT202200283T1 (it) 2022-09-14
EP3157534A1 (de) 2017-04-26

Similar Documents

Publication Publication Date Title
EP4512471A3 (de) Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen
WO2015017328A3 (en) Organophosphates for treating afflictions of the skin
WO2016010984A3 (en) Compositions and methods for treating rosacea
MX377544B (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BR112016028964A2 (pt) métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
HK1246232A1 (zh) 用於治疗非酒精性脂肪肝病的acc抑制剂组合治疗
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
WO2014107740A3 (en) Methods for reducing cellular proliferation and treating certain diseases
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX381164B (es) Composiciones tópicas de corticosteroides.
EA201991790A1 (ru) Терапевтические препараты апремиласта для местного применения
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
MX376183B (es) Composiciones para el tratamiento de rosacea.
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
HK1258762A1 (zh) Btk抑制剂gs-4059与选自jak、ask1、brd和/或mmp9抑制剂的抑制剂的组合，以治疗癌症、过敏性病症、自身免疫疾病或发炎性疾病
MX377447B (es) Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
MX381311B (es) Método para el tratamiento de prurito y/o comezón.
BR112019005815A2 (pt) métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3157534

Country of ref document: EP

Kind code of ref document: P

Ref document number: 4088724

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0017000000

Ipc: A61K0031270000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 57/20 20060101ALI20250331BHEP

Ipc: A61P 33/00 20060101ALI20250331BHEP

Ipc: A61P 17/00 20060101ALI20250331BHEP

Ipc: A61K 31/683 20060101ALI20250331BHEP

Ipc: A61K 31/662 20060101ALI20250331BHEP

Ipc: A61K 31/55 20060101ALI20250331BHEP

Ipc: A61K 31/473 20060101ALI20250331BHEP

Ipc: A61K 31/27 20060101AFI20250331BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260311